COVID-19 and the pulmonary complications of sickle cell disease

被引：14

作者：

Sivalingam, Thivya ^{[1
]}

Inusa, Baba ^{[2
]}

Doyle, Pat ^{[3
]}

Oteng-Ntim, Eugene ^{[4
]}

机构：

[1] Kings Coll London, Fac Life Sci & Med, GKT Sch Med, London, England

[2] Guys & St Thomas Hosp NHS Fdn Trust, Evelina Childrens Hosp, Dept Paediat, London, England

[3] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Dept Noncommunicable Dis Epidemiol, London, England

[4] Guys & St Thomas Hosp NHS Fdn Trust, Dept Obstet & Gynaecol, London, England

来源：

EJHAEM | 2020年 / 1卷 / 02期

关键词：

infection; sickle cell anemia; sickle cell disease; therapy; viruses;

D O I：

10.1002/jha2.105

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Sickle cell disease (SCD) patients are commonly affected by pulmonary complications such as acute chest syndrome (ACS), pulmonary embolism (PE) and pneumonia that contribute to significant mortality risks. With a greater susceptibility to infection, they are deemed to be vulnerable patients during the current COVID-19 pandemic. In emerging small case studies of SCD patients with COVID-19 and further complicated by pneumonia, ACS, and/or PE, the clinical benefits of early exchange transfusion and Tocilizumab are evident. However, further clinical trials and larger cohort studies are essential to evaluate effective diagnostic and management options for this high-risk group.

引用

页码：545 / 547

页数：3

共 15 条

[1]

[Anonymous], Coronavirus (COVID-19) Infection Survey technical article: waves and lags of COVID-19 in England, June 2021

[2]

Arlet J-B., 2020, Lancet Haematol, V80, P19

[3] COVID-19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient [J].

Beerkens, Frans ;

John, Mira ;

Puliafito, Benjamin ;

Corbett, Virginia ;

Edwards, Colleen ;

Tremblay, Douglas .

AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (07) :E154-E156

[4] Infection in sickle cell disease: A review [J].

Booth, Catherine ;

Inusa, Baba ;

Obaro, Stephen K. .

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 (01) :E2-E12

[5] Why tocilizumab could be an effective treatment for severe COVID-19? [J].

Fu, Binqing ;

Xu, Xiaoling ;

Wei, Haiming .

JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)

[6] Pathogenesis and treatment of acute chest syndrome of sickle-cell anaemia [J].

Gladwin, MT ;

Rodgers, GP .

LANCET, 2000, 355 (9214) :1476-1478

[7] Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected with Pulmonary CT Angiography [J].

Grillet, Franck ;

Behr, Julien ;

Calame, Paul ;

Aubry, Sebastien ;

Delabrousse, Eric .

RADIOLOGY, 2020, 296 (03) :E186-E188

[8] Vaso-occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19) [J].

Nur, Erfan ;

Gaartman, Aafke E. ;

van Tuijn, Charlotte F. J. ;

Tang, Man Wai ;

Biemond, Bart J. .

AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (06) :725-726

[9] Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome [J].

Odievre, Marie-Helene ;

de Marcellus, Charles ;

Ducou Le Pointe, Hubert ;

Allali, Slimane ;

Romain, Anne-Sophie ;

Youn, Jenny ;

Taytard, Jessica ;

Nathan, Nadia ;

Corvol, Harriet .

AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (08) :E192-E194

[10] Low morbidity and mortality with COVID-19 in sickle cell disease: A single center experience [J].

Ramachandran, Preethi ;

Perisetti, Abhilash ;

Kathirvelu, Balachandar ;

Gajendran, Mahesh ;

Ghanta, Snigdha ;

Onukogu, Ifeanyichkwu ;

Lao, Ted ;

Anwer, Faiz .

EJHAEM, 2020, 1 (02) :608-614

← 1 2 →